NeoCircle: pre- and post-operative circulating tumor DNA dynamics…
Blood tests detecting lingering cancer cells after breast cancer treatment can predict recurrence over a year earlier than standard imaging or clinical signs.
- Lab
- Preclinical
- Early trials
- Late trials
- In practice
Compound EGFR mutations are predominantly PACC (P-loop and alpha-C…
A common lung cancer mutation pattern responds equally well to standard targeted drugs, helping doctors avoid treatment delays from misclassification.
Novel or significantly improved treatmentAmivantamab plus chemotherapy vs. chemotherapy as first-line…
A new antibody drug combined with chemotherapy doubled progression-free survival for a specific lung cancer mutation in Chinese patients, validating global trial results locally.
Near-term implementable findingEASL-AASLD Delphi consensus statement on surrogate endpoints and…
International consensus guidelines now provide clear frameworks for approving promising liver disease treatments previously stuck in regulatory limbo.
Standard additionOptimized PET/CT response assessment for prognostic stratification…
Refined PET imaging criteria better predict which lymphoma patients will relapse, enabling early treatment adjustments to improve outcomes.